Lucid Diagnostics Inc (LUCD NASDAQ) stock market data APIs
$1.4829
0.07(4.9%)
as of March 18, 2025
Lucid Diagnostics Inc Financial Data Overview
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Prev. Close
1.4172
Open
1.4829
High
1.4841
Low
1.3702
52 wk Range
0.6301-1.633
Market Cap
118 M
Shares Outstanding
83 636 K
Revenue
4 189 K
EPS
-0.2
Beta
1.342
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Lucid Diagnostics Inc data using free add-ons & libraries
Get Lucid Diagnostics Inc Fundamental Data
Lucid Diagnostics Inc Fundamental data includes:
- Net Revenue: 4 189 K
- EBITDA: -43 556 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-13
- EPS/Forecast: -0.22
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Lucid Diagnostics Inc News
New
PAVmed to Hold a Business Update Conference Call and Webcast on August 16, 2023
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 31, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical techn...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 15, 2023
Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, July 31, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medic...
Lucid Diagnostics to Present at the Canaccord Genuity 43rd Annual Growth Conference
NEW YORK, July 26, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary...
PAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare Coverage
Advocated stronger transparency and predictability, and inclusion of diagnostics, in federal proposals to improve equitable access to innovative lifesaving technologies Highlighted EsoGuard's life-sa...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
